Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management

Brookstone Capital Management boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 11.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,155 shares of the biopharmaceutical company’s stock after acquiring an additional 18,516 shares during the quarter. Brookstone Capital Management’s holdings in Bristol-Myers Squibb were worth $10,529,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Trust Co. of Toledo NA OH raised its holdings in Bristol-Myers Squibb by 21.8% during the 4th quarter. Trust Co. of Toledo NA OH now owns 46,679 shares of the biopharmaceutical company’s stock worth $2,640,000 after buying an additional 8,341 shares during the period. Fiduciary Alliance LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $253,000. Aprio Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb by 72.9% in the 4th quarter. Aprio Wealth Management LLC now owns 8,282 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 3,493 shares in the last quarter. Czech National Bank grew its stake in shares of Bristol-Myers Squibb by 6.5% in the 4th quarter. Czech National Bank now owns 439,749 shares of the biopharmaceutical company’s stock valued at $24,872,000 after buying an additional 26,747 shares in the last quarter. Finally, West Oak Capital LLC grew its stake in shares of Bristol-Myers Squibb by 2,608.1% in the 4th quarter. West Oak Capital LLC now owns 40,350 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 38,860 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $55.35 on Tuesday. The business has a fifty day simple moving average of $57.44 and a 200 day simple moving average of $51.66. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm has a market capitalization of $112.26 billion, a price-to-earnings ratio of -15.42, a PEG ratio of 15.20 and a beta of 0.45. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. Bristol-Myers Squibb’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.00 earnings per share. Sell-side analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.48%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently -69.08%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. UBS Group boosted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Barclays boosted their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.